Une histoire qui commencera au S2 17 - ACHAT - OC 5,5€
Suite à sa publication de ses résultats 2016, la biotech française a organisé un rendez-vous investisseurs dans le but de revenir sur les différents catalyseurs cliniques de 2017. Côté trésorerie, avec un cash burn d’environ 30m€, la visibilité financière s’étend jusqu’au S2 2018. Les premiers résultats cliniques de TG4010 en combinaison avec Opdivo en 2ndL NSCLC seront le principal catalyseur de cette année (premiers résultats attendus au S2 17). En parallèle, une collaboration pourrait être annoncée d’ici là dans le NSCLC 1L. Recommandation ACHAT maintenu.Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.